Showing results (1401-1410 of 1,520) with videos related to

Sort By:
Pageof 152
Clinical Trials (London, England)|October 25, 2023
Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1Liny John, Gurbani Singh, Eva Dombi, et al.
Frontiers in Oncology|May 6, 2024
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancersNebojsa Skorupan, Cody J Peer, Xianyu Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2022
Genetic variation within the human papillomavirus type 16 genome is associated with oropharyngeal cancer prognosisK A Lang Kuhs, D L Faden, L Chen, et al.
Blood|April 4, 2002
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacyWyndham H Wilson, Michael L Grossbard, Stefania Pittaluga, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 28, 2016
Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host DiseaseFilip Pirsl, Lauren M Curtis, Seth M Steinberg, et al.
Blood Advances|March 15, 2021
Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseasesRamya Ramaswami, Kathryn Lurain, Mark N Polizzotto, et al.
Oncogene|February 24, 2015
Cigarette smoke mediates epigenetic repression of miR-217 during esophageal adenocarcinogenesisS Xi, S Inchauste, H Guo, et al.
Cancer Immunology, Immunotherapy : CII|September 20, 2011
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patientsOsama E Rahma, Ed Ashtar, Malgorzata Czystowska, et al.
Blood Advances|October 4, 2021
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variantDai Chihara, Evgeny Arons, Maryalice Stetler-Stevenson, et al.
Neuro-Oncology|February 7, 2014
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C Widemann, Eva Dombi, Andrea Gillespie, et al.
Pageof 152